title: Aberrant expression of the microRNA cluster in 14q32 is associated with del(5q) myelodysplastic syndrome and lenalidomide treatment.
abstract: Lenalidomide is a novel thalidomide analogue with immunomodulatory and antiangiogenic effects that has been successfully used for the treatment of low and intermediate-1 risk myelodysplastic syndromes (MDSs) with a del(5q) aberration. Because information about the influence of lenalidomide on the microRNA (miRNA) transcriptome is limited, we performed miRNA expression profiling of bone marrow CD34+ cells obtained from MDS patients with the del(5q) abnormality who had been subjected to lenalidomide treatment. To define differences in miRNA expression, we performed paired data analysis to compare the miRNA profiles of patients before and during lenalidomide treatment and those of healthy donors. The analysis showed that miRNAs clustering to the 14q32 region had a higher expression level in patient samples before treatment than in the healthy control samples, and this elevated expression was diminished following lenalidomide administration. Because some of the 14q32 miRNAs play important roles in hematopoiesis, stem cell differentiation, and apoptosis induction, the expression of this cluster may be associated with the pathophysiology of the disease.
authors.affiliation: Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
authors.forename: Zdeněk
authors.initials: Z
authors.lastname: Krejčík
authors.affiliation: Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
authors.forename: Monika
authors.initials: M
authors.lastname: Beličková
authors.affiliation: Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
authors.forename: Andrea
authors.initials: A
authors.lastname: Hruštincová
authors.affiliation: Department of Computer Science, Faculty of Electrical Engineering, Czech Technical University, Prague, Czech Republic.
authors.forename: Jiří
authors.initials: J
authors.lastname: Kléma
authors.affiliation: Center of Oncocytogenetics, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic.
authors.forename: Zuzana
authors.initials: Z
authors.lastname: Zemanová
authors.affiliation: Institute of Hematology and Blood Transfusion, Prague, Czech Republic; Center of Oncocytogenetics, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic.
authors.forename: Kyra
authors.initials: K
authors.lastname: Michalová
authors.affiliation: Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
authors.forename: Jaroslav
authors.initials: J
authors.lastname: Čermák
authors.affiliation: First Department of Medicine, General University Hospital, Prague, Czech Republic.
authors.forename: Anna
authors.initials: A
authors.lastname: Jonášová
authors.affiliation: Institute of Hematology and Blood Transfusion, Prague, Czech Republic. Electronic address: michaela.merkerova@uhkt.cz.
authors.forename: Michaela
authors.initials: M
authors.lastname: Dostálová Merkerová
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D016022:Case-Control Studies; D002872:Chromosome Deletion; D002883:Chromosomes, Human, Pair 14 / Q000235:genetics*; D002895:Chromosomes, Human, Pair 5 / Q000235:genetics; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D000077269:Lenalidomide; D035683:MicroRNAs / Q000235:genetics*; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics*; D020411:Oligonucleotide Array Sequence Analysis; D017384:Sequence Deletion; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D007155:Immunologic Factors; D035683:MicroRNAs; D013792:Thalidomide; D000077269:Lenalidomide
keywords: 14q32; del(5q); lenalidomide; miRNA; myelodysplastic syndrome